Efpia Sustainability Profile
The European Federation of Pharmaceutical Industries and Associations (EFPIA), headquartered in Belgium, represents the pharmaceutical industry across Europe. Founded in 1978, EFPIA plays a pivotal role in advocating for the interests of its members, which include leading pharmaceutical companies and national associations. The organisation focuses on key areas such as research and development, access to medicines, and healthcare policy. With a commitment to innovation, EFPIA supports initiatives that enhance patient access to high-quality treatments while promoting sustainable healthcare systems. Its unique position as a bridge between the pharmaceutical industry and European policymakers enables it to influence critical discussions on health and medicine. Notable achievements include significant contributions to public health and the advancement of regulatory frameworks that benefit both patients and the industry.
DitchCarbon Score
How does Efpia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Efpia's score of 36 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Efpia's reported carbon emissions
In 2022, Efpia reported significant carbon emissions totalling approximately 97,100,000,000 kg CO2e across all scopes. This includes about 8,900,000,000 kg CO2e from Scope 1 emissions, approximately 4,900,000,000 kg CO2e from Scope 2, and a substantial 97,100,000,000 kg CO2e from Scope 3 emissions. Efpia has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 emissions by 46% by 2030, using a 2019 baseline. Furthermore, the organisation has a long-term goal to achieve a 95% reduction in these emissions by 2040. These targets reflect a strong commitment to addressing climate change and reducing the overall carbon footprint of the pharmaceutical industry. The emissions data is sourced directly from Efpia, with no cascading from parent or related organisations. The organisation's initiatives align with industry standards for climate action, demonstrating a proactive approach to sustainability and environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 8,900,000,000 |
| Scope 2 | 4,900,000,000 |
| Scope 3 | 97,100,000,000 |
How Carbon Intensive is Efpia's Industry?
How Carbon Intensive is Efpia's Location?
Efpia's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Efpia has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
